Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Dicerna Pharmaceuticals stock price, quote, forecast and news

DRNA
US2530311081
A1XCYU

Price

38.22
Today +/-
+0
Today %
+0 %
P

Dicerna Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Dicerna Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Dicerna Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Dicerna Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Dicerna Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Dicerna Pharmaceuticals Stock Price History

DateDicerna Pharmaceuticals Price
12/29/202138.22 undefined
12/28/202138.22 undefined

Dicerna Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Dicerna Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Dicerna Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Dicerna Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Dicerna Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Dicerna Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Dicerna Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Dicerna Pharmaceuticals’s growth potential.

Dicerna Pharmaceuticals Revenue, EBIT and net profit per share

DateDicerna Pharmaceuticals RevenueDicerna Pharmaceuticals EBITDicerna Pharmaceuticals Net Income
2025e169.51 M undefined-113.9 M undefined-111.8 M undefined
2024e170.98 M undefined-160.32 M undefined-149.22 M undefined
2023e175.91 M undefined-230.18 M undefined-203.16 M undefined
2022e205.94 M undefined-167.18 M undefined-154.87 M undefined
2021e182.47 M undefined-139.05 M undefined-130.17 M undefined
2020164.3 M undefined-113.2 M undefined-112.7 M undefined
201923.9 M undefined-128.2 M undefined-120.5 M undefined
20186.2 M undefined-61.3 M undefined-88.9 M undefined
20171 M undefined-51.7 M undefined-60.2 M undefined
2016300,000 undefined-59.7 M undefined-59.5 M undefined
2015200,000 undefined-63 M undefined-62.8 M undefined
20140 undefined-45.1 M undefined-47.9 M undefined
20130 undefined-17.4 M undefined-18.5 M undefined
20127 M undefined-9.3 M undefined-10.1 M undefined
20117.9 M undefined-7.6 M undefined-8.6 M undefined

Dicerna Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021e2022e2023e2024e2025e
7700001623164182205175170169
-------500.00283.33613.0410.9812.64-14.63-2.86-0.59
---------------
000000000000000
-7-9-17-45-63-59-51-61-128-113-139-167-230-160-113
-100.00-128.57-----5,100.00-1,016.67-556.52-68.90-76.37-81.46-131.43-94.12-66.86
-8-10-18-47-62-59-60-88-120-112-130-154-203-149-111
-25.0080.00161.1131.91-4.841.6946.6736.36-6.6716.0718.4631.82-26.60-25.50
10.610.610.616.120.320.721.955.668.474.200000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Dicerna Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Dicerna Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020
                   
22.53.746.696.194.645.9113.7302.6348.9568.8
0.2500000000
0000000000
0000000000
0.40.42.11.11.51.43.42.15.213.8
23.19.148.797.296.147.3117.1304.7354.1582.6
1.30.90.92.22.72.21.52.737.278.4
0002.5000000
0000000000
0000000000
0000000000
0.30.30.31.61.21.20.80.84.110.8
1.61.21.26.33.93.42.33.541.389.2
24.710.349.9103.510050.7119.4308.2395.4671.8
                   
60.264.2110.20000000
0016.5231.7287.3297417605.5677.5775.8
-50.6-64.7-85.5-133.4-196.2-255.8-316-404.8-525.3-638.1
0000000000
0000000000
9.6-0.541.298.391.141.2101200.7152.2137.7
1.41.21.71.22.64.34.956.17.9
0.20.31.33.86.45.75.720.123.431.5
0.80.10.10.1006.268.9212.3138.5
0000000000
2.84.14.60000000
5.25.77.75.191016.894241.8177.9
8.74.70.30000000
0000000000
1.10.30.50.1003.1114.3203.5392.2
9.850.80.1003.1114.3203.5392.2
1510.78.55.291019.9208.3445.3570.1
24.610.249.7103.5100.151.2120.9409597.5707.8
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Dicerna Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Dicerna Pharmaceuticals's financial health and stability.

Assets

Dicerna Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Dicerna Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Dicerna Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Dicerna Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020
-8-10-18-47-62-59-60-88-120-112
0000000012
0000000000
0-56130689100232
-1-1010997171752
01,00000000000
0000000000
-8-15-10-34-48-48-45180175
000-2-1000-6-11
000-753313-19-20249-258
000-733413-19-20255-247
0000000000
7-2-1-5000000
0057954501131705259
7-354904501121695259
---1.00-------
0000000000
-2-1843-2030-3547-14101-24
0000000000
0000000000

Dicerna Pharmaceuticals stock margins

The Dicerna Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dicerna Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dicerna Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Dicerna Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Dicerna Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Dicerna Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Dicerna Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Dicerna Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Dicerna Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Dicerna Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Dicerna Pharmaceuticals Margin History

Dicerna Pharmaceuticals Gross marginDicerna Pharmaceuticals Profit marginDicerna Pharmaceuticals EBIT marginDicerna Pharmaceuticals Profit margin
2025e0 %-67.19 %-65.96 %
2024e0 %-93.77 %-87.28 %
2023e0 %-130.85 %-115.49 %
2022e0 %-81.18 %-75.2 %
2021e0 %-76.2 %-71.33 %
20200 %-68.9 %-68.59 %
20190 %-536.4 %-504.18 %
20180 %-988.71 %-1,433.87 %
20170 %-5,170 %-6,020 %
20160 %-19,900 %-19,833.33 %
20150 %-31,500 %-31,400 %
20140 %0 %0 %
20130 %0 %0 %
20120 %-132.86 %-144.29 %
20110 %-96.2 %-108.86 %

Dicerna Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Dicerna Pharmaceuticals earnings per share therefore indicates how much revenue Dicerna Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Dicerna Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Dicerna Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Dicerna Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Dicerna Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Dicerna Pharmaceuticals Revenue, EBIT and net profit per share

DateDicerna Pharmaceuticals Sales per ShareDicerna Pharmaceuticals EBIT per shareDicerna Pharmaceuticals Earnings per Share
2025e2.24 undefined0 undefined-1.48 undefined
2024e2.26 undefined0 undefined-1.97 undefined
2023e2.32 undefined0 undefined-2.68 undefined
2022e2.72 undefined0 undefined-2.04 undefined
2021e2.41 undefined0 undefined-1.72 undefined
20202.21 undefined-1.53 undefined-1.52 undefined
20190.35 undefined-1.87 undefined-1.76 undefined
20180.11 undefined-1.1 undefined-1.6 undefined
20170.05 undefined-2.36 undefined-2.75 undefined
20160.01 undefined-2.88 undefined-2.87 undefined
20150.01 undefined-3.1 undefined-3.09 undefined
20140 undefined-2.8 undefined-2.98 undefined
20130 undefined-1.64 undefined-1.75 undefined
20120.66 undefined-0.88 undefined-0.95 undefined
20110.75 undefined-0.72 undefined-0.81 undefined

Dicerna Pharmaceuticals business model

Dicerna Pharmaceuticals Inc. is a biopharmaceutical company based in the United States that focuses on RNA interference (RNAi). It was founded in 2007 and is headquartered in Lexington, Massachusetts. It also has branches in Germany and Switzerland. Dicerna Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Dicerna Pharmaceuticals SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Dicerna Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Dicerna Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Dicerna Pharmaceuticals shares outstanding

The number of shares was Dicerna Pharmaceuticals in 2023 — This indicates how many shares 74.2 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Dicerna Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Dicerna Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Dicerna Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Dicerna Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
7.14650 % Eli Lilly and Company5,414,18504/1/2021
5.97480 % BlackRock Institutional Trust Company, N.A.4,526,50721,6589/30/2021
5.12959 % State Street Global Advisors (US)3,886,1811,297,1199/30/2021
4.89336 % The Vanguard Group, Inc.3,707,21086,8579/30/2021
4.06578 % Bain Capital Life Sciences Investors, LLC3,080,23709/30/2021
3.54091 % T. Rowe Price Associates, Inc.2,682,596699,6719/30/2021
3.24260 % Aquilo Capital Management, LLC2,456,595643,2039/30/2021
2.12232 % Morgan Stanley & Co. LLC1,607,870626,3099/30/2021
10.00844 % RTW Investments L.P.7,582,39660,5379/30/2021
1.78465 % Woodline Partners LP1,352,048351,7239/30/2021
1
2
3
4
5
...
10

Dicerna Pharmaceuticals Executives and Management Board

Dr. Douglas Fambrough52
Dicerna Pharmaceuticals Chief Executive Officer (since 2021)
Compensation 6.62 M
Dr. Ralf Rosskamp67
Dicerna Pharmaceuticals Chief Medical Officer (since 2017)
Compensation 4.33 M
Mr. John Green65
Dicerna Pharmaceuticals Chief Financial Officer, Principal Financial Officer (since 2016)
Compensation 4.01 M
Mr. Robert Ciappenelli54
Dicerna Pharmaceuticals Chief Commercial Officer, Chief Strategy Officer (since 2021)
Compensation 3.56 M
Dr. Bob Brown56
Dicerna Pharmaceuticals Executive Vice President, Research and Development, Chief Scientific Officer (since 2019)
Compensation 3.36 M
1
2
3
4
5
...
6

Most common questions regarding Dicerna Pharmaceuticals

What values and corporate philosophy does Dicerna Pharmaceuticals represent?

Dicerna Pharmaceuticals Inc represents values of innovation, scientific excellence, and patient-centricity. The company is committed to advancing RNA interference (RNAi) technology to develop transformative therapies. By leveraging its GalXC™ platform, Dicerna aims to deliver targeted and durable treatments for patients with unmet medical needs. With a focus on precision medicine, Dicerna values collaboration, integrity, and social responsibility. By prioritizing patient well-being, Dicerna Pharmaceuticals Inc strives to make a significant impact on human health by developing breakthrough therapies that address the underlying causes of diseases.

In which countries and regions is Dicerna Pharmaceuticals primarily present?

Dicerna Pharmaceuticals Inc is primarily present in the United States. As a biopharmaceutical company, Dicerna focuses on the development of innovative RNA interference (RNAi) therapeutics. With headquarters located in Lexington, Massachusetts, Dicerna operates primarily within the United States.

What significant milestones has the company Dicerna Pharmaceuticals achieved?

Dicerna Pharmaceuticals Inc has achieved several significant milestones. The company successfully developed and commercialized RNA interference (RNAi) therapies, demonstrating their expertise in the field. In 2018, Dicerna received approval from the U.S. Food and Drug Administration for their lead product, Patisiran, for the treatment of patients with rare hereditary transthyretin amyloidosis (hATTR). Dicerna also expanded its pipeline with promising preclinical and clinical programs targeting a wide range of diseases, including liver, cardiovascular, and viral diseases. Moreover, the company established strategic collaborations with renowned pharmaceutical companies to further enhance their research and development capabilities. These achievements highlight Dicerna Pharmaceuticals Inc's dedication to advancing innovative therapies and addressing unmet medical needs.

What is the history and background of the company Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals Inc. is a leading biopharmaceutical company specializing in the discovery and development of RNA interference (RNAi) therapeutics. Founded in 2007, Dicerna aims to harness the power of RNAi to create targeted therapeutics for patients with rare diseases and disorders. The company's innovative platform enables the design and optimization of potent RNAi molecules that can selectively silence disease-causing genes. Dicerna's commitment to scientific excellence and strategic partnerships has led to significant advancements in RNAi therapeutics, making them a recognized leader in the field. With a focus on addressing unmet medical needs, Dicerna Pharmaceuticals Inc. continues to pave the way for cutting-edge treatments using RNAi technology.

Who are the main competitors of Dicerna Pharmaceuticals in the market?

Dicerna Pharmaceuticals Inc faces competition from various companies in the market. Some of its main competitors include Alnylam Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc. These companies also specialize in developing RNA interference (RNAi) therapeutics and share a similar focus on innovative treatments for various diseases. However, Dicerna Pharmaceuticals Inc distinguishes itself through its proprietary RNAi technology platform and its pipeline of potential therapies targeting unmet medical needs.

In which industries is Dicerna Pharmaceuticals primarily active?

Dicerna Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals Inc is a biopharmaceutical company that focuses on discovering and developing innovative RNAi-based therapeutics. Their business model revolves around utilizing their proprietary GalXC™ RNAi platform to develop medicines that silence genes causing disease. By harnessing the potential of RNA interference, Dicerna aims to address a variety of diseases with unmet medical needs. With a strong commitment to scientific excellence and collaboration, Dicerna Pharmaceuticals Inc strives to bring transformative treatments to patients while creating value for shareholders.

What is the P/E ratio of Dicerna Pharmaceuticals 2024?

The Dicerna Pharmaceuticals P/E ratio is -19.

What is the P/S ratio of Dicerna Pharmaceuticals 2024?

The Dicerna Pharmaceuticals P/S ratio is 16.59.

What is the AlleAktien quality score of Dicerna Pharmaceuticals?

The AlleAktien quality score for Dicerna Pharmaceuticals is 4/10.

What is the revenue of Dicerna Pharmaceuticals 2024?

The expected Dicerna Pharmaceuticals revenue is 170.98 M USD.

How high is the profit of Dicerna Pharmaceuticals 2024?

The expected Dicerna Pharmaceuticals profit is -149.22 M USD.

What is the business model of Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Inc is a publicly traded biopharmaceutical company based in Lexington, Massachusetts, specializing in RNAi technology (RNA interference). The company was founded in 2007 and currently employs around 150 employees.

What is the Dicerna Pharmaceuticals dividend?

Dicerna Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Dicerna Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Dicerna Pharmaceuticals or the company does not pay out a dividend.

What is the Dicerna Pharmaceuticals ISIN?

The ISIN of Dicerna Pharmaceuticals is US2530311081.

What is the Dicerna Pharmaceuticals WKN?

The WKN of Dicerna Pharmaceuticals is A1XCYU.

What is the Dicerna Pharmaceuticals ticker?

The ticker of Dicerna Pharmaceuticals is DRNA.

How much dividend does Dicerna Pharmaceuticals pay?

Over the past 12 months, Dicerna Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dicerna Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Dicerna Pharmaceuticals?

The current dividend yield of Dicerna Pharmaceuticals is .

When does Dicerna Pharmaceuticals pay dividends?

Dicerna Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Dicerna Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Dicerna Pharmaceuticals located?

Dicerna Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dicerna Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dicerna Pharmaceuticals from 9/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did Dicerna Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/12/2024.

What was the dividend of Dicerna Pharmaceuticals in the year 2023?

In the year 2023, Dicerna Pharmaceuticals distributed 0 USD as dividends.

In which currency does Dicerna Pharmaceuticals pay out the dividend?

The dividends of Dicerna Pharmaceuticals are distributed in USD.

All fundamentals about Dicerna Pharmaceuticals

Our stock analysis for Dicerna Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dicerna Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.